| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.TRSL.2014.08.002 |
| P698 | PubMed publication ID | 25218118 |
| P2093 | author name string | James A Shayman | |
| P2860 | cites work | Effect of allopurinol in chronic kidney disease progression and cardiovascular risk | Q24630327 |
| The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group | Q27861088 | ||
| The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy | Q28237978 | ||
| Cardiorenal end points in a trial of aliskiren for type 2 diabetes | Q28278569 | ||
| Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 | ||
| The renal dopaminergic system: novel diagnostic and therapeutic approaches in hypertension and kidney disease. | Q30360038 | ||
| TNF superfamily: a growing saga of kidney injury modulators. | Q30479123 | ||
| Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism | Q30544587 | ||
| US Renal Data System 2012 Annual Data Report | Q30582337 | ||
| Avosentan for overt diabetic nephropathy | Q33702404 | ||
| Bardoxolone methyl and kidney function in CKD with type 2 diabetes | Q34194954 | ||
| Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease | Q34383685 | ||
| Effects of urate-lowering therapy in hyperuricemia on slowing the progression of renal function: a meta-analysis | Q34468472 | ||
| Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial | Q34625011 | ||
| The proteinuria-hypertriglyceridemia connection as a basis for novel therapeutics for nephrotic syndrome. | Q34735597 | ||
| Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial | Q34787799 | ||
| Active vitamin D treatment for reduction of residual proteinuria: a systematic review | Q34912750 | ||
| Therapeutic targets for treating fibrotic kidney diseases | Q35079607 | ||
| Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes | Q35721420 | ||
| The endothelin system and its antagonism in chronic kidney disease | Q36422620 | ||
| Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease | Q36788430 | ||
| Surrogate end points for clinical trials of kidney disease progression | Q36910445 | ||
| NADPH oxidase-dependent redox signaling in TGF-β-mediated fibrotic responses. | Q37541098 | ||
| PAI-1 in tissue fibrosis | Q37861626 | ||
| Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney? | Q37979621 | ||
| Novel therapeutic strategy with hypoxia-inducible factors via reversible epigenetic regulation mechanisms in progressive tubulointerstitial fibrosis | Q38134937 | ||
| Novel therapeutic approaches to autosomal dominant polycystic kidney disease | Q38273327 | ||
| The USRDS: what you need to know about what it can and can't tell us about ESRD. | Q39525751 | ||
| Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. | Q40509707 | ||
| Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease | Q40600194 | ||
| Renal function in gout: long-term treatment effects of febuxostat | Q42683725 | ||
| Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial | Q43626458 | ||
| Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. | Q43725750 | ||
| Retarding progression of chronic renal disease: the neglected issue of residual proteinuria | Q44445107 | ||
| Uric acid and the state of the intrarenal renin-angiotensin system in humans | Q44598792 | ||
| Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials | Q46567269 | ||
| A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. | Q50578930 | ||
| Intensive glucose control improves kidney outcomes in patients with type 2 diabetes | Q57312402 | ||
| Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy | Q57704237 | ||
| Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease | Q83489879 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 482-487 | |
| P577 | publication date | 2014-08-19 | |
| P1433 | published in | Translational Research | Q15761127 |
| P1476 | title | Challenges and opportunities in the development of therapeutics for chronic kidney disease | |
| P478 | volume | 165 |
Search more.